Alaunos Therapeutics (Alaunos Therapeutics) Pre-Tax Income

: $-35.14 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Alaunos Therapeutics's pretax income for the three months ended in Dec. 2023 was $-7.84 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.14 Mil. Alaunos Therapeutics's pretax margin was -784,300.00%.

During the past 13 years, Alaunos Therapeutics's highest Pretax Margin was -850.26%. The lowest was -702800.00%. And the median was -2590.67%.

Alaunos Therapeutics Pre-Tax Income Historical Data

The historical data trend for Alaunos Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-117.80

-79.98

-78.75

-37.73

-35.14

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income																-9.16	-10.05	-8.77	-8.48	-7.84

Competitive Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Pre-Tax Income falls into.

Alaunos Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Alaunos Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-28.493	+	-4.726	+	-1.921	+	0	+	0
	=	-35.14

Alaunos Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.36	+	-4.483	+	0	+	0	+	0
	=	-7.84

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.14 Mil.

Alaunos Therapeutics (NAS:TCRT) Pre-Tax Income Explanation

Alaunos Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-7.843	/	0.001
	=	-784,300.00%

During the past 13 years, Alaunos Therapeutics's highest Pretax Margin was -850.26%. The lowest was -702800.00%. And the median was -2590.67%.

Alaunos Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Executives

Boyle Kevin S. Sr.	director, officer: Chief Executive Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser	director	ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma	director	141 MECOX ROAD, WATER MILL NY 11976
Michael Wong	officer: VP, Finance	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava	officer: See Remarks	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis	director	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden	director	38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger	officer: VP, Research & Development	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De	officer: EVP, Operations	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey	officer: Senior Vice President, Legal	C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen	director	AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa	officer: Chief Medical Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129